Close Menu

Tech Review reports on a new study from the Journal of Clinical Oncology that provides a link between personalized medicine and better health outcomes. For the study, oncologist Lecia Sequist genetically screened patients' lung cancers and then administered a drug tailored for that type of tumor — and those patients did better than the average chemotherapy outcomes. In particular, the study looked at AstraZeneca's Iressa, an EGFR inhibitor.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.